Market Newsdesk

TORONTO, March 08, 2021 (GLOBE NEWSWIRE) — SideDrawer, the API-first client-facing document collaboration platform, is pleased to announce a significant investment from The David Slabodkin Family Trust (“The Trust”). David Slabodkin was the Founder & CEO of Canada Protection Plan, and recently exited the business through a sale to Foresters Financial, a leading North American insurance underwriter.

“We are thrilled to have an insurance pioneer like David support our vision. Canada Protection Plan was built on the premise of helping Canadians, establishing itself as a leading provider of life insurance and related products distributed through 28,000 independent life insurance advisors. Life insurance sales, similar to financial planning, mortgages, loans, property and casualty insurance, and many other routine engagements, rely heavily on email for receiving and delivering sensitive client data. With increasing awareness of cybersecurity risks and data security, businesses and consumers want a better experience around these processes. We believe David’s deep insurance expertise will be a significant benefit as we expand our insurance and related financial distribution channels,” said J. Gaston Siri, Co-Founder & CEO of SideDrawer.  

“As the family moves forward from Canada Protection Plan, we are focused on advancing businesses and technologies that benefit society. We view the protection and privacy of data as a fundamental right for people and a primary concern for consumers. The SideDrawer team has created a unique platform which will not only help individuals be prepared for life changes but allows businesses and enterprises to integrate the flexible technology to help their clients. We think SideDrawer is a unique offering, and something we believe every individual will benefit from,” said Max Fine, on behalf of The David Slabodkin Family Trust.

“We are very excited to contribute to the digital transformation for client experience around secure document collaboration. Currently this experience remains quite challenging, and has not evolved with enhancements found in other business functions. Our objective is to offer businesses the ability to collaborate with customers in a secure and engaging manner. With this additional investment, we will grow our team and infrastructure to support our SMB and enterprise clients. We know business priorities and product roadmaps can shift; as such, our solution can allow resources to be focused on enhancing core products, while easily integrating SideDrawer’s APIs for better document workflows, access controls, engagement features, and analytics,” said Ali Qureshi, Chief Revenue Officer & Co-Founder of SideDrawer.

Along with The Trust’s investment, SideDrawer is making the following appointments to its Board of Directors and Advisory Board:

Board of Directors appointments

• Peter Andreana – Peter is a Partner at Continuum II Inc., a leading wealth management firm in Canada. He is an established financial literacy expert with experience across financial planning, insurance, business succession, group benefits and pensions. A majority of Peter’s current role is working with business owners to help them grow, prosper, and maintain continuous success. Peter coincidentally was an early adopter of SideDrawer for his practice, and recognized the value add the platform brought to his business and clients. We are fortunate to have Peter’s insight to continuously enhance our product and navigate the needs of the financial sector professionals.

• Max Fine – Max is a product and UX designer with a background in industrial design.  Max’s previous experience includes founding Bender Inc. a startup that is currently developing a digital retail platform. He has spent the past 2 years at thinktum Inc. focusing on the customer facing side of product design mainly in the fintech, insurtech and healthcare industries. He has also served on the Board of The Nourish and Develop Foundation for the past 12 years. Max will represent the interests of The David Slabodkin Family Trust and their new business endeavours. The family is focused on advancing businesses and technologies that benefit society.

Advisory Board appointments

• Paul Reaburn – Paul is an Actuary by training and an exceptionally seasoned life insurance executive. Paul was formerly the President & CEO, and Chairman of Aegon Canada; Executive VP and CFO of Foresters Financial; and, currently the CFO of insurtech platform, thinktum Inc. Paul is leading efforts to expand thinktum’s technology and grow its North American customer base. He is also assisting The David Slabodkin Family Trust with its overall investment opportunities. Paul’s deep roots in every aspect of the insurance, wealth management, and pension industry should contribute to new revenue opportunities and distribution channels for SideDrawer.

Any business interested in exploring a customizable, client collaboration and engagement platform should contact us at [email protected].

LinkedIn bios:

• Peter Andreana – https://www.linkedin.com/in/peterandreana/
• Max Fine – https://www.linkedin.com/in/max-fine-0a396b1b9/
• Paul Reaburn – https://www.linkedin.com/in/paul-reaburn-2b043a7/

About SideDrawer

SideDrawer is a technology company that focuses on improving the client experience around data collaboration and organization for businesses of all sizes. From a turnkey, client-facing solution for individuals, professionals and SMBs, to APIs for fintechs and enterprises, we aim to improve productivity and increase client engagement, all within a secure environment. With a completely flexible architecture, SideDrawer’s APIs can easily integrate with any enterprise to customize and enhance the web and mobile client experience. For more information, please visit: www.sidedrawer.com or download our mobile apps on the Apple App Store or Google Play Store, or sign up at https://my.sidedrawer.com. 

Contact:
Ali Qureshi
+1 855 663 7070
[email protected]

SAN JOSE, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Synaptics Incorporated (Nasdaq: SYNA) (the “Company” or “Synaptics”) today announced that it intends to offer, subject to market and other conditions, $400 million aggregate principal amount of senior unsecured notes due 2029 (the “Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be unsecured, senior obligations of the Company and will be guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under its credit facility. The interest rate and certain other terms of the Notes will be determined at the time of the pricing of the offering.

The Company expects to use the net proceeds from the sale of the Notes to repay the $100 million of borrowings under its revolving credit facility and for general corporate purposes, which may include, among other things, to prefund the repayment of a portion of its existing 0.50 percent convertible senior notes due 2022 (the “Existing 2022 Notes”) and to pay any and all expenses, fees and costs associated therewith, including the payment of accrued and unpaid interest on such Existing 2022 Notes, future acquisitions, additional repayment of existing indebtedness and repurchases of shares of the Company’s common stock.

The exact timing and terms of the offering will depend on market conditions and other factors.

The Notes have not been and are not expected to be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offers of the securities will be made only by means of a private offering memorandum.

About Synaptics Incorporated:

Synaptics (Nasdaq: SYNA) is changing the way humans engage with connected devices and data, engineering exceptional experiences throughout the home, at work, in the car and on the go. Synaptics is the partner of choice for the world’s most innovative intelligent system providers who are integrating multiple experiential technologies into platforms that make our digital lives more productive, insightful, secure and enjoyable. These customers are combining Synaptics’ differentiated technologies in touch, display and biometrics with a new generation of advanced connectivity and AI-enhanced video, vision, audio, speech and security processing. Follow Synaptics on LinkedIn, Twitter and Facebook, or visit synaptics.com.

Special Note Regarding Forward-Looking Statements:

This press release contains forward-looking statements that are subject to the safe harbors created under the Securities Act and the Securities Exchange Act of 1934, as amended. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business, including the Company’s expectations regarding the transactions described in this press release and the anticipated use of proceeds therefrom, and can be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements may include words such as “expect,” “anticipate,” “intend,” “believe,” “estimate,” “plan,” “target,” “strategy,” “continue,” “may,” “will,” “should,” variations of such words, or other words and terms of similar meaning. All forward-looking statements reflect the Company’s best judgment and are based on several factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. Such factors include, but are not limited to: the Company’s inability to price and close the offering of the Notes; the Company’s dependence on its solutions for the mobile product applications market and the PC product applications market for a substantial portion of its revenue; risks related to the volatility of the Company’s net revenue from its solutions for mobile product applications; the Company’s dependence on one or more large customers; the risk that the Company’s business, results of operations and financial condition (including liquidity) and prospects may be materially and adversely affected by heath epidemics, including the COVID-19 pandemic; the Company’s exposure to industry downturns and cyclicality in its target markets; the risk that the Company’s product solutions for new markets will not be successful; the Company’s ability to maintain and build relationships with its customers; the Company’s dependence on third parties to maintain satisfactory manufacturing yields and deliverable schedules; and the risks as identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended June 27, 2020 (including that the impact of the COVID-19 pandemic may also exacerbate the risks discussed therein) and other risks as identified from time to time in the Company’s Securities and Exchange Commission reports. Forward-looking statements are based on information available to the Company on the date hereof, and it does not have, and expressly disclaims, any obligation to publicly release any updates or any changes in its expectations, or any change in events, conditions, or circumstances on which any forward-looking statement is based. The Company’s actual results and the timing of certain events could differ materially from the forward-looking statements. These forward-looking statements do not reflect the potential impact of any mergers, acquisitions, or other business combinations that had not been completed as of the date of this release.

For further information, please contact:

Jason Tsai
Head of Investor Relations
[email protected]

Houston, March 08, 2021 (GLOBE NEWSWIRE) — Shell Midstream Partners, L.P. (NYSE: SHLX) has announced that the Partnership’s 2020 investor K-1 tax packages are now available on its website, http://www.shellmidstreampartners.com. Investors may access the tax package portal via a link on the “Tax Information” page, or use the following direct link: https://www.partnerdatalink.com/Shell

For additional information related to the 2020 K-1 tax package, please contact [email protected] or call toll-free 1-855-288-4071. 

# # #

About Shell Midstream Partners, L.P.

Shell Midstream Partners, L.P., headquartered in Houston, Texas, owns, operates, develops and acquires pipelines and other midstream and logistics assets. The Partnership’s assets include interests in entities that own (a) crude oil and refined products pipelines and terminals that serve as key infrastructure to  transport onshore and offshore crude oil production to Gulf Coast and Midwest refining markets and  deliver refined products from those markets to major demand centers and (b) storage tanks and financing receivables that are secured by pipelines, storage tanks, docks, truck and rail racks and other infrastructure used to stage and transport intermediate and finished products. The Partnership’s assets also include interests in entities that own natural gas and refinery gas pipelines that transport offshore natural gas to market hubs and deliver refinery gas from refineries and plants to chemical sites along the Gulf Coast.

For more information on Shell Midstream Partners and the assets owned by the Partnership, please visit
www.shellmidstreampartners.com.

Inquiries: 
Shell Media Relations: +1 832 337 4355
Shell Investor Relations North America: +1 832 337 2034

* SHELL and the SHELL Pecten are registered trademarks of Shell Trademark Management, B.V. used under license.

SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has been appointed general counsel.

“Alex brings extensive operational and regulatory experience in the life sciences industry that will help him build our company’s legal function,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “He is a dynamic leader with deep roots in the fields of business, government and law. I am pleased to welcome him to our team and believe his expertise will serve us well as we continue to advance our clinical pipeline in ophthalmology and other age-related diseases.”

Mr. Nguyen previously worked for three Roivant Sciences companies where he served as general counsel at Alyvant, head of legal at Axovant, and as head of compliance at Roivant Sciences. His responsibilities included all corporate legal work, SEC filings, equity financings, venture debt deals, licensing agreements, corporate governance at board meetings, litigation, internal investigations, asset recovery, HR, IT, compliance, and risk management. He also led the drafting and negotiation of term sheets and oversaw due diligence for acquisition of commercial-stage assets. Before that, he handled a wide range of high-stakes litigation and investigations in the private as well as the public sector, including as deputy section chief and federal prosecutor at the U.S. Attorney’s Offices in Alexandria and Philadelphia, respectively, successfully leading dozens of cases involving cybercrime, data breaches, IP and trade secrets violations, FDA regulatory offenses, illegal importation of adulterated and misbranded pharmaceuticals, prescription drug diversion, white collar crime, identity theft and tax violations.

Mr. Nguyen also served as assistant White House counsel, managing and implementing key White House policy initiatives across Cabinet and federal agencies. He obtained his undergraduate degree from Harvard University and his law degree from Yale Law School.

About UNITY

UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Investors 
Gilmartin Group
Matt Lane
[email protected]

Media
Canale Communications
Jason Spark
[email protected] 

AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) — Phunware, Inc. (NASDAQ: PHUN) (“Phunware” or “the Company”) a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, will be presenting at the 33^rd Annual Roth Conference, which is being held virtually on March 15-17.

Phunware management has recorded the presentation, which is available for replay here, and will be attending one-on-one meetings throughout the conference.

To receive additional information or to schedule a one-on-one meeting, please contact Phunware’s IR team at [email protected].   

About Phunware, Inc.

Everything You Need to Succeed on Mobile — Transforming Digital Human Experience
Phunware, Inc. (NASDAQ: PHUN), is the pioneer of Multiscreen-as-a-Service (MaaS), an award-winning, fully integrated enterprise cloud platform for mobile that provides companies the products, solutions, data and services necessary to engage, manage and monetize their mobile application portfolios and audiences globally at scale. Phunware’s Software Development Kits (SDKs) include location-based services, mobile engagement, content management, messaging, advertising, loyalty (PhunCoin & Phun) and analytics, as well as a mobile application framework of pre-integrated iOS and Android software modules for building in-house or channel-based mobile application and vertical solutions. Phunware helps the world’s most respected brands create category-defining mobile experiences, with more than one billion active devices touching its platform each month. For more information about how Phunware is transforming the way consumers and brands interact with mobile in the virtual and physical worlds visit www.phunware.com, www.phuncoin.com, www.phuntoken.com, and follow @phunware, @phuncoin and @phuntoken on all social media platforms.

Investor Relations Contact:

Matt Glover and John Yi
Gateway Investor Relations
Email: [email protected]
Phone: (949) 574-3860

PR & Media Inquiries:

Email: [email protected]
Phone: (512) 693-4199

FORT WORTH, Texas, March 08, 2021 (GLOBE NEWSWIRE) — Contango Oil & Gas Company (NYSE American: MCF) (“Contango” or the “Company”) announced today that it plans to issue its fourth quarter 2020 earnings release before market open on Wednesday, March 10, 2021. In conjunction with the release, Contango will conduct a conference call to discuss the contents of that release on Wednesday, March 10, 2021 at 8:00 am Central Standard Time. A presentation related to certain items to be discussed on the call will be posted to the Company’s website at ir.contango.com prior to the call. 

Teleconference Call

Those interested in participating in the earnings conference call may do so by clicking here and entering your information to be connected. The link becomes active 15 minutes prior to the scheduled start time, and the conference coordinator will call you. If you are not at a computer, you can join by dialing +1 (323)-347-3622 (International 800-309-1256) and entering participation code 898661. A replay of the call will be available Thursday, March 11, 2021 through Thursday, March 18, 2021 by clicking here.

About Contango Oil & Gas Company

Contango Oil & Gas Company is a Fort Worth, Texas based, independent oil and natural gas company whose business is to maximize production and cash flow from its offshore properties in the shallow waters of the Gulf of Mexico and onshore properties primarily located in  Oklahoma, Texas,  Wyoming  and Louisiana  and, when determined appropriate, to use that cash flow to explore, develop, exploit, and increase production from its existing properties, to acquire additional PDP-heavy crude oil and natural gas properties or to pay down debt. Additional information is available on the Company’s website at http://www.contango.com. Information on our website is not part of this release.

Contact:

Contango Oil & Gas Company
E. Joseph Grady – 713-236-7400
Senior Vice President and Chief Financial and Accounting Officer

Dr. Paul Walker will remain on the Board of Directors focusing on the seamless transition of management and on ensuring continuity of the Tigris Trial

TORONTO, March 08, 2021 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced the appointment of Chris Seto to Chief Executive Officer (“CEO”), effective April 1, 2021. In his new role, Mr. Seto will continue to serve as the Company’s Chief Financial Officer (“CFO”). Dr. Paul Walker, current CEO, will remain committed to the Company as a member of the Board of Directors, where he will be responsible for a seamless transition of leadership, and focus his efforts on the Tigris Trial supporting Dr. John Kellum, Spectral’s recently announced Chief Medical Officer.

Previously, Mr. Seto was responsible for overseeing the financial and operational management of the Company including, finance, accounting, treasury and capital markets, as well as corporate planning and development, and investor relations. Prior to joining Spectral Medical, Mr. Seto was the CFO of MJardin Group Inc. (CSE:MJAR) and GrowForce Holdings Inc. Mr. Seto has over 25 years of capital markets and financial management experience, including senior investment banking positions with Paradigm Capital, UBS Securities and CIBC World Markets; and financial management experience in the telecom and healthcare industries with Bell Canada and Warren Shepell. Mr. Seto holds a B. Comm. from McMaster University, an MBA from the Richard Ivey School of Business, and a Certified Management Accountant designation (C.M.A. 1999).

“I would like to thank Dr. Walker and the Board of Directors for their confidence in my ability to lead Spectral to achieve growth in product commercialization, revenues and earnings in due course. I look forward to working with the Spectral team to continue on the exciting path we have developed for our Company under the leadership of Dr. Walker,” said Chris Seto, COO and CFO of Spectral Medical. “Over the last year we refined our corporate structure, including the recent appointment of Dr. John Kellum as Chief Medical Officer, which will make this transition seamless while maintaining our team’s focus on achieving our key corporate priorities.”

Dr. Walker commented, “I am very pleased that Chris is transitioning to the Chief Executive Officer position. Since joining the Company, Chris has demonstrated outstanding operational and financial leadership, and has played a key role in defining our strategy for the Dialco subsidiary. With the recent addition of Dr. John Kellum to our organization, I am confident that we are well positioned to successfully complete the Tigris Trial and to advance our scientific and product development agenda for Spectral.”  

Anthony Bihl, Chairman of Spectral, further noted, “Chris’ transition to CEO is a reflection of his unwavering commitment and outstanding leadership. Moreover, I would like to personally express our sincere gratitude to Dr. Paul Walker, who has successfully led the organization over the last twenty years through a transition from a diagnostic focused company to a leading theranostics company focused on bringing unique commercial products to market—positioning us for long-term success. As one of the world’s leading experts on endotoxin and its role in sepsis, as well as the co-inventor of the Endotoxin Activity Assay (EAA™), we look forward to his continued contributions as we advance the Tigris Trial.”

About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new proprietary platform, “SAMI”, targeting the renal replacement therapy (“RRT”) market. Dialco is also seeking regulatory approval for in-home use of “DIMI” which is based on the same RRT platform, but will be intended for home hemodialysis use. “DIMI” recently received its FDA 510k clearance for use in hospital and clinical settings.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.

Forward Looking Statement

Information in this news release that is not current or historical factual information may constitute forward-looking information or forward looking statements within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities including but not limited to the ongoing impact of COVID-19. Actual results could differ materially from what is currently expected, and readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Reference is also made to the other risks and uncertainties that may affect the Company which are more fully described in Spectral’s Annual Information Form dated March 26, 2020 and other filings of Spectral with the securities regulatory authorities which are available at

www.sedar.com

.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

Contact:
Mr. Chris Seto	Mr. Ali Mahdavi	David Waldman/Natalya Rudman
COO & CFO	Capital Markets & Investor	US Investor Relations
Spectral Medical Inc.	Relations	Crescendo Communications, LLC
416-626-3233 ext. 2004	416-962-3300	212-671-1020
[email protected]	[email protected]	[email protected]

TEMPE, Ariz., March 08, 2021 (GLOBE NEWSWIRE) — VirTra, Inc. (NASDAQ: VTSI), a global provider of training simulators for the law enforcement, military, educational, and commercial markets will be presenting at the 33^rd Annual Roth Conference, which is being held virtually on March 15-17.

VirTra’s chairman and CEO, Bob Ferris, will hold one-on-one meetings with institutional investors and analysts throughout the conference.

To receive additional information or to schedule a one-on-one meeting, please contact VirTra’s IR team at [email protected].

About VirTra

VirTra (NASDAQ: VTSI) is a global provider of judgmental use of force training simulators, firearms training simulators and driving simulators for the law enforcement, military, educational and commercial markets. The company’s patented technologies, software, and scenarios provide intense training for de-escalation, judgmental use-of-force, marksmanship and related training that mimics real-world situations. VirTra’s mission is to save and improve lives worldwide through practical and highly effective virtual reality and simulator technology. Learn more about the company at www.VirTra.com.

Investor Relations Contact:
Matt Glover or Charlie Schumacher
[email protected]
949-574-3860

NASHUA, N.H., March 08, 2021 (GLOBE NEWSWIRE) — iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 171,516 shares of common stock. The Company received total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) of approximately $25.0 million. The Company intends to use the net proceeds of the offering for working capital and general corporate purposes.

Guggenheim Securities acted as sole book-running manager for the offering. JMP Securities, Craig-Hallum Capital Group, and Lake Street Capital Markets, LLC acted as lead managers for the offering and Laidlaw & Company (UK) Ltd. and Colliers Securities LLC acted as co-managers for the offering.

The securities described above were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-235887) previously filed with the Securities and Exchange Commission (“SEC”) on January 10, 2020, which registration statement was declared effective on January 31, 2020 and an additional registration statement on Form S-3MEF (File No. 333-253808) filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, on March 2, 2021, which registration statement became automatically effective upon filing.

A final prospectus supplement relating to the offering dated March 2, 2021 was filed with the SEC on March 4, 2021 and is available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may also be obtained from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

Forward-Looking Statements
Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For example, when the Company discusses the anticipated use of proceeds from the proposed offering, it is using forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, increase sales and acceptance of products, adoption by CMS of a new payment model, and that such model will prove beneficial to the Company, which is not assured, implement expansion plans, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, to successfully defend itself in litigation matters, government regulation, changes in Medicare or other reimbursement policies, risks relating to the Company’s existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company, the effects of a global pandemic, and other risks detailed in the Company’s filings with the SEC. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by the Company, please see the disclosure contained in the Company’s public filings with the SEC, available on the Investors section of the Company’s website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
[email protected]

Investor Relations:
Jeremy Feffer, LifeSci Advisors
+ 1-212-915-2568
[email protected]